Date: 2011-09-27
Type of information: R&D agreement
Compound: low molecular weight natural products to treat microbial infections
Company: Hypha Discovery (UK) Ferrer Grupo (Spain)
Therapeutic area: Infectious diseases
Type agreement: R&D
Action mechanism:
Disease: microbial infections
Details: Hypha has announced a collaboration with Ferrer Grupo to mine Hypha\'s MycoDiverse™ library to discover novel low molecular weight natural products to treat microbial infections. Hypha's library will provide an important complement to Ferrer\'s synthetic chemistry-driven discovery programme. This collection of 10,000 refined fractions from fermentations of higher fungi has been generated using Hypha’s proprietary technology to stimulate secondary metabolite production. The collection contains a very high percentage of relatively low molecular weight (MW <500) and undescribed compounds and is a proven source of novel lead compounds against “difficult” therapeutic targets, including protein-protein interactions.
Financial terms:
Latest news:
